It's rare to see a supplement so directly problematic for a drug, but inositol regulation may be how lithium works in the brain. As such, patients wanting to supplement with inositol could be inactivating their lithium. Definitely discuss and monitor with your physician.
Here's a link to the August 2010 study and here's the abstract below. Another study looks at the complexities of the interaction (inositol supplementation might even be helpful, but don't chance it.)
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 26. [Epub ahead of print]
Association analysis between polymorphisms in the myo-inositol monophosphatase 2 (IMPA2) gene and bipolar disorder.
Bloch PJ, Weller AE, Doyle GA, Ferraro TN, Berrettini WH, Hodge R, Lohoff FW.
Psychiatric Pharmacogenetics Laboratory, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Linkage studies in bipolar disorder (BPD) suggest that a susceptibility locus exists on chromosome 18p11. The myo-inositol monophosphatase 2 gene (IMPA2) maps to this genomic region. Myo-inositol monophosphatase dephosphorylates inositol monophosphate, regenerating free inositol. Lithium, a common treatment for BPD, has been shown to inhibit IMPA2 activity and decrease levels of inositol. It is hypothesized that lithium conveys its therapeutic effect for BPD patients partially through inositol regulation. Hence, dysfunction of inositol caused by IMPA2 irregularity may contribute to the pathophysiology of BPD. In this study, we hypothesize that genetic variations in the IMPA2 gene contributes to increased susceptibility to BPD. We tested this hypothesis by genotyping 9 SNPs (rs1787984; rs585247; rs3974759; rs650727; rs589247; rs669838; rs636173; rs3786285; rs613993) in BPD patients (n=556) and controls (n=735). Genotype and allele frequencies were compared between groups using Chi square contingency analysis. Linkage disequilibrium (LD) between markers was calculated and estimated haplotype frequencies were compared between groups. Single marker analysis revealed several associations between IMPA2 variations and BPD, which were subsequently rendered non-significant after correction for multiple testing. Although our study did not show strong support for an association between the tested IMPA2 polymorphisms and susceptibility to BPD, additional larger studies are necessary to comprehensively investigate a role of the IMPA2 gene in the pathophysiology of BPD.
Copyright © 2010 Elsevier Inc. All rights reserved.